Day: February 18, 2022

North Arrow Extends Loan Agreement with Anglo Celtic Exploration

North Arrow Extends Loan Agreement with Anglo Celtic Exploration

VANCOUVER, British Columbia, Feb. 18, 2022 (GLOBE NEWSWIRE) — North Arrow Minerals Inc. (TSXV-NAR) (“North Arrow”) announces that it has agreed with Anglo Celtic Exploration Ltd (“Anglo Celtic”) to extend by one year the term of an unsecured loan of $400,000 (the “Loan”) provided to North Arrow and first announced on February 17, 2021. Under terms of the amendment to the loan agreement (the “Agreement”) the revised date by which any outstanding balance on the loan must be repaid in full is February 16, 2023. All other terms related to the Loan and the Agreement remain the same. As further consideration for agreeing to extend the Loan, North Arrow shall issue to Anglo Celtic 1,000,000 share purchase warrants (the “Bonus Warrants”). Each Bonus Warrant will allow Anglo Celtic to purchase one common share (a “Warrant Share”) at a price...

Continue reading

Intema closes Livestream Gaming acquisition in escrow

Intema closes Livestream Gaming acquisition in escrow

The Corporation satisfies conditions to acquire Livestream Gaming and triggers automatic exercise of subscription receipts into common shares and warrants of Intema. Livestream Gaming is the parent company of LOOT.BET, a top online gaming platform and brand in the esports betting space. The acquisition will be accretive to Intema’s revenues: Livestream Gaming recorded gross gaming revenue of 2.2 million euros for the year ended December 31, 2021 (3.2 million euros in 2020). LOOT.BET will benefit from the recently granted Isle of Man online gaming license and Intema’s growing esports and iGaming ecosystem. MONTREAL, Feb. 18, 2022 (GLOBE NEWSWIRE) — Intema Solutions Inc. (“Intema” or the “Corporation”) (TSXV: ITM, OTCMKTS: ITMZF) is pleased to announce that the Corporation has satisfied the outstanding conditions for the release...

Continue reading

Pinnacle Bankshares Corporation Announces Fourth Quarter and 2021 Earnings

Pinnacle Bankshares Corporation Announces Fourth Quarter and 2021 Earnings

ALTAVISTA, Va., Feb. 18, 2022 (GLOBE NEWSWIRE) — Net income for Pinnacle Bankshares Corporation (OTCQX:PPBN), the one-bank holding company (“Pinnacle” or the “Company”) for First National Bank (“First National” or the “Bank”), was $473,000, or $0.22, per basic and diluted share, for the quarter ended December 31, 2021, and $4,375,000, or $2.02, per basic and per diluted share, for the year ended December 31, 2021.   Net income was $1,487,000, or $0.76 per basic and diluted share, and $3,062,000, or $1.85 per basic share and $1.84 per diluted share, respectively, for the same periods of 2020.   Consolidated results for the fourth quarter and the full year 2021 are unaudited. The $4,375,000 in net income generated during 2021 represents a $1,314,000, or 43%, increase as compared to the prior year, which was primarily driven by higher...

Continue reading

Ocugen, Inc. Announces U.S. FDA Lifts Clinical Hold on the Submission of Its Investigational New Drug Application for Its COVID-19 Vaccine Candidate COVAXIN™ (BBV152)

Ocugen, Inc. Announces U.S. FDA Lifts Clinical Hold on the Submission of Its Investigational New Drug Application for Its COVID-19 Vaccine Candidate COVAXIN™ (BBV152)

MALVERN, Pa., Feb. 18, 2022 (GLOBE NEWSWIRE) — Ocugen, Inc. (NASDAQ: OCGN), a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics and vaccines, announced that the U.S. Food and Drug Administration (FDA) has lifted its clinical hold on the Company’s Investigational New Drug application (IND) to evaluate the COVID-19 vaccine candidate, BBV152, known as COVAXIN™ outside the United States. COVAXIN™ is a whole-virion inactivated COVID-19 investigational vaccine candidate that uses the same vero cell manufacturing platform that has been used in the production of polio vaccines for decades. “We are pleased to be able to move our clinical program for COVAXIN™ forward, which we hope will bring us closer to offering an alternative COVID-19 vaccine,” said Dr. Shankar Musunuri,...

Continue reading

HV Bancorp, Inc. Reports Results for the Year Ended December 31, 2021

HV Bancorp, Inc. Reports Results for the Year Ended December 31, 2021

DOYLESTOWN, Pa., Feb. 18, 2022 (GLOBE NEWSWIRE) — HV Bancorp, Inc. (the “Company” or “HVB”) (Nasdaq Capital Market: HVBC), the holding company of Huntingdon Valley Bank (the “Bank”), reported operating results for the year ended December 31, 2021. Net income for the year ended December 31, 2021, was $4.1 million ($2.04 per basic share of common stock and $1.98 per diluted share of common stock) versus net income of $5.8 million ($2.84 per basic and diluted shares of common stock) for the year ended December 31, 2020. This resulted in shareholders’ equity increasing 9.5% from $38.9 million at December 31, 2020, to $42.6 million at December 31, 2021, and book value per share increasing from $17.78 per share of common to 19.64 per share of common stock over the same period. Net income for the quarter ended December 31, 2021 was $351,000...

Continue reading

Timbercreek Financial Declares February 2022 Dividend

Timbercreek Financial Declares February 2022 Dividend

TORONTO, Feb. 18, 2022 (GLOBE NEWSWIRE) — Timbercreek Financial (TSX: TF) (the “Company”) is pleased to announce that it has declared a monthly cash dividend of $0.0575 per common share (“Common Share”) of the Company to be paid on March 15, 2022 to holders of Common Shares of record on February 28, 2022. The Company also offers a Dividend Reinvestment Plan (the “Plan”), which is eligible to holders of Common Shares and provides a convenient means to purchase additional Common Shares by reinvesting cash dividends at a potential discount and without having to pay commissions, service charges or brokerage fees. Pursuant to the Plan and at the discretion of Timbercreek Capital Inc., the Manager, Common Shares will be acquired in the open market at prevailing prices or issued from treasury at 98 percent of the average market price...

Continue reading

Data from Codiak’s exoASO™-STAT6 Preclinical Development Program for the Treatment of Primary and Metastatic Hepatic Cancers Published in Science Advances

Data from Codiak’s exoASO™-STAT6 Preclinical Development Program for the Treatment of Primary and Metastatic Hepatic Cancers Published in Science Advances

– Unprecedented monotherapy activity via macrophage reprogramming in preclinical models – – Phase 1 study expected to begin in 1H 2022 – CAMBRIDGE, Mass., Feb. 18, 2022 (GLOBE NEWSWIRE) — Codiak BioSciences, Inc. (NASDAQ: CDAK), a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics as a new class of medicines, today announced the online publication of a new manuscript, Exosome mediated genetic reprogramming of tumor associated macrophages by exoASO-STAT6 leads to potent monotherapy anti-tumor efficacy, in the American Association for the Advancement of Science’s journal, Science Advances. exoASO™-STAT6 is a novel, engineered exosome precision medicine candidate in development for the treatment of macrophage-rich tumors. This publication details the findings from the preclinical development...

Continue reading

Nokia Corporation: Repurchase of own shares on 18.02.2022

Nokia Corporation: Repurchase of own shares on 18.02.2022

Nokia CorporationStock Exchange Release18 February 2022 at 21:00 EET Nokia Corporation: Repurchase of own shares on 18.02.2022 Espoo, Finland – On 18 February 2022 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: Trading venue (MIC Code) Number of shares Weighted average price / share, EUR* XHEL 244,696 5.07 CEUX 19,997 5.07 AQEU 3,147 5.09 TQEX 2,060 5.11 Total 269,900 5.07 * Rounded to two decimals On 3 February 2022, Nokia announced that its Board of Directors is initiating a share buyback program under the current authorization granted by Nokia’s Annual General Meeting on 8 April 2021 to return up to EUR 600 million of cash to shareholders in traches over a period of two years. The first phase of the share buyback program in compliance with the Market Abuse Regulation...

Continue reading

PURA Farmersville Hemp Brand Potential Fueled By Over 20,000 Confirmed Hemp Growers Surveyed By USDA

PURA Farmersville Hemp Brand Potential Fueled By Over 20,000 Confirmed Hemp Growers Surveyed By USDA

Dallas, Texas, Feb. 18, 2022 (GLOBE NEWSWIRE) — Puration, Inc. (OTC Pink: PURA) has launched an initiative to expand the utilization of hemp worldwide under the brand name Farmersville Hemp. PURA is building a co-op of hemp growers and processors to raise market awareness around the multitude of yet to be realized uses of hemp and build a brand name to benefit all co-op participants under the name Farmersville Hemp. Yesterday, the U.S. Department of Agriculture (USDA) published the first ever survey on the newly legal hemp industry.  The report drew on over 20,000 surveyed growers. PURA anticipates generating at least $1 million in revenue in 2022 with the potential to reach $10 million in revenue.  The $10 million revenue opportunity outlook is improving based on the recent progress of PURA’s co-op partners. PURA is scheduled...

Continue reading

Notice convening the Annual General Meeting of Dampskibsselskabet NORDEN A/S

Notice convening the Annual General Meeting of Dampskibsselskabet NORDEN A/S

ANNOUNCEMENT NO. 45 – 18 FEBRUARY 2022 18 February 2022 Notice is hereby given that the annual general meeting will convene in Dampskibsselskabet NORDEN A/Sat 2.00 p.m. CET on Thursday 24 March 2022, at the Copenhagen Marriott Hotel, meeting room Vesterhavet I, Kalvebod Brygge 5, 1560 Copenhagen V The Annual General Meeting will be held as a hybrid general meeting allowing for either physical or electronic participation. After the general meeting NORDEN will host a canapé reception. AGENDA:         A.        The Board of Directors’ report on the activities of the Company during the past year.         B.        Resolution for adoption of the audited Annual Report.                                 C.        Proposed appropriation of profits or cover of loss in accordance with the adopted annual report.                         D.         Election...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.